Dinoges-EV - Dienogest + Estradiol Valerate | VetSafeCare.Com

Tab.

Dinoges-EV

Dienogest + Estradiol Valerate — Nuvista Pharma Ltd.
(2mg + 2mg) / tablet

Alternatives

1

Routes

PO

Presentations

1

Generic profile Browse alternatives View combinations

Presentations

Tablet · (2mg + 2mg) / tablet

1 tablet

৳1680

Dose rules

No structured dose rules are linked to this brand yet.

Dose reference

Human

Take one tablet daily by mouth at the same time every day. Tablets must be taken in the order directed on the blister pack. Do not skip or delay intake by more than 12 hours. 

Clinical notes

Applications:

N/A

Indication Notes:
This is an estrogen/progestin COC, indicated for use by women to prevent pregnancy. The efficacy of this tablet in women with a body mass index (BMI) of >30 kg/m 2 has not been evaluated. Treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception.
Avoid In:

N/A

Contraindication Notes:
A high risk of arterial or venous thrombotic diseases Undiagnosed abnormal uterine bleeding Breast cancer or other estrogens- or progestin-sensitive cancer
COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.
Drugs or herbal products that induce certain enzymes (for example CYP3A4) may decrease the effectiveness of COCs or increase breakthrough bleeding. Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with COCs.
The most common adverse reactions (≥2%) in clinical trials for Natazia are headache (including migraines) 13%, breast pain 7%, menstrual disorders 7%, nausea or vomiting 6%, acne 4%, mood changes (3%) and increased weight 3%.
Vascular risks: Stop this tablet if a thrombotic event occurs. Stop this tablet at least 4 weeks before and through 2 weeks after major surgery. Start this tablet no earlier than 4 weeks after delivery, in women who are not breastfeeding. Liver disease: Discontinue this tablet if jaundice occurs. High blood pressure: Do not prescribe this tablet for women with uncontrolled hypertension or hypertension with vascular disease. Carbohydrate and lipid metabolic effects: Monitor prediabetic and diabetic women taking this tablet. Consider an alternate contraceptive method for women with uncontrolled dyslipidemia. Headache: Evaluate significant change in headaches and discontinue this tablet if indicated. Uterine bleeding: Evaluate irregular bleeding or amenorrhea. CYP3A4 induction: Women taking strong CYP3A4 inducers (for example, carbamazepine, phenytoin, rifampicin, and St. John’s wort) should not choose this tablet as their oral contraceptive due to the possibility of decreased contraceptive efficacy.